DexCom Aktie
WKN: A0D9T1 / ISIN: US2521311074
13.01.2025 15:00:24
|
DexCom Q4 Preliminary Revenue Improves; Pre-Market Stock Up
(RTTNews) - DexCom, Inc. (DXCM), a maker of continuous glucose monitoring systems for diabetes management, on Monday reported a rise in preliminary revenue for the fourth quarter. For the fourth quarter, the company reported preliminary revenue of at least $1.113 billion, up 8 percent from the same period last year. The U.S. revenue is expected to be approximately $803 million, representing a year-on-year growth of 4 percent.
For the full-year 2024, preliminary revenue stood at approximately $4.032 billion, an increase of 11 percent over 2023.
Kevin Sayer, CEO of DexCom, said: "Dexcom made key strategic investments in 2024 that steadily progressed throughout the year, leaving us well positioned to capitalize on our growth opportunity ahead. We plan to build on these investments in 2025 by further enhancing our differentiated product portfolio and advocating for greater CGM access globally."
Looking ahead, for the full-year 2025, Dexcom currently anticipates revenue of $4.60 billion, representing a growth of approximately 14 percent over 2024. This guidance considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics.
Dexcom will release its annual earnings report on February 13.
DXCM was up by 5.47 percent at $82.01 in the pre-market trade on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu DexCom Inc.mehr Nachrichten
20:05 |
NASDAQ Composite aktuell: So steht der NASDAQ Composite nachmittags (finanzen.at) | |
20:05 |
Zuversicht in New York: S&P 500 liegt am Nachmittag im Plus (finanzen.at) | |
20:05 |
Dienstagshandel in New York: So entwickelt sich der NASDAQ 100 aktuell (finanzen.at) | |
16:04 |
NASDAQ Composite Index-Titel DexCom-Aktie: So viel hätte eine Investition in DexCom von vor 5 Jahren gekostet (finanzen.at) | |
16:03 |
Zurückhaltung in New York: NASDAQ Composite verliert zum Start (finanzen.at) | |
16:03 |
S&P 500-Handel aktuell: S&P 500 verbucht zum Start Verluste (finanzen.at) | |
16:03 |
NASDAQ-Handel NASDAQ 100 präsentiert sich zum Start leichter (finanzen.at) | |
25.06.25 |
Zuversicht in New York: NASDAQ 100 steigt letztendlich (finanzen.at) |
Analysen zu DexCom Inc.mehr Analysen
Aktien in diesem Artikel
DexCom Inc. | 71,33 | -3,26% |
|